首页> 外文期刊>Journal of proteome research >Sequencing and quantifying igg fragments and antigen-binding regions by mass spectrometry
【24h】

Sequencing and quantifying igg fragments and antigen-binding regions by mass spectrometry

机译:通过质谱法对igg片段和抗原结合区进行测序和定量

获取原文
获取原文并翻译 | 示例
           

摘要

In cancer and autoimmune diseases, immunoglobulins with a specific molecular signature that could potentially be used as diagnostic or prognostic markers are released into body fluids. An immunomics approach based on this phenomenon relies on the ability to identify the specific amino acid sequences of the complementarity-determining regions (CDR) of these immunoglobulins, which in turn depends on the level of accuracy, resolution, and sensitivity that can be achieved by advanced mass spectrometry. Reproducible isolation and sequencing of antibody fragments (e.g., Fab) by high-resolution mass spectrometry (MS) from seven healthy donors revealed 43 217 MS signals: 225 could be associated with CDR1 peptides, 513 with CDR2 peptides, and 19 with CDR3 peptides. Seventeen percent of the 43 217 MS signals did not overlap between the seven donors. The Fab isolation method used is reproducible and fast, with a high yield. It provides only one Fab sample fraction for subsequent characterization by high-resolution MS. In 17% and 4% of these seven healthy donors, qualitative (presence/absence) and quantitative (intensity) differences in Fab fragments could be demonstrated, respectively. From these results, we conclude that the identification of a CDR signature as biomarker for autoimmune diseases and cancer without prior knowledge of the antigen is feasible.
机译:在癌症和自身免疫性疾病中,具有特定分子特征的免疫球蛋白可能会被用作诊断或预后标志物,并释放到体液中。基于此现象的免疫组学方法依赖于识别这些免疫球蛋白互补决定区(CDR)特定氨基酸序列的能力,而后者又取决于可以通过以下方法实现的准确性,分辨率和敏感性水平:先进的质谱。可通过高分辨率质谱(MS)对来自七个健康供体的抗体片段(例如Fab)进行可重现的分离和测序,结果显示43 217个MS信号:其中225个与CDR1肽相关,513个与CDR2肽相关,19个与CDR3肽相关。 43 217个MS信号中有17%的七个供体之间没有重叠。所用的Fab分离方法可重现且快速,产率高。它仅提供一个Fab样品馏分,用于随后的高分辨率MS表征。在这七个健康供体中的17%和4%中,可以分别证明Fab片段的质量(存在/不存在)和数量(强度)差异。根据这些结果,我们得出结论,无需抗原的先验知识就可以将CDR签名鉴定为自身免疫性疾病和癌症的生物标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号